振东制药股价波动，政策利好中药工业高质量发展

Group 1: Industry Overview - The Ministry of Industry and Information Technology and seven other departments issued the "Implementation Plan for High-Quality Development of Traditional Chinese Medicine Industry (2026-2030)", aiming to cultivate 60 high-standard traditional Chinese medicine raw material production bases and establish 5 innovation centers by 2030, providing favorable policies for traditional Chinese medicine companies [1] - The traditional Chinese medicine industry is expected to enter a rapid transformation period over the next five years, driven by policies that will enhance industry concentration and promote collaborative innovation across the supply chain [4] Group 2: Company Performance - As of February 12, 2026, the stock price of Zhen Dong Pharmaceutical was reported at 6.13 yuan, with a daily decline of 2.70% but a cumulative increase of 6.79% over the past five days; the trading volume was 251 million yuan with a turnover rate of 4.11% [2] - The financial report for the first three quarters of 2025 showed that Zhen Dong Pharmaceutical's revenue was 2.215 billion yuan, a year-on-year decrease of 2.42%; net profit attributable to shareholders was 20.3641 million yuan, down 49.25%; however, the non-recurring net profit increased by 101.67% to 507,500 yuan, and the net profit for the third quarter alone grew by 31.34% year-on-year [3] - In the main business, traditional Chinese medicine accounted for 54.82% and chemical medicine accounted for 43.10% of the company's revenue [3]